GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 40.6 Billion KRW | -32.44% |
| 2022 | 49.41 Billion KRW | 36.27% |
| 2021 | 36.26 Billion KRW | 21.4% |
| 2020 | 29.87 Billion KRW | 41.58% |
| 2019 | 21.09 Billion KRW | -3.91% |
| 2018 | 21.95 Billion KRW | -28.05% |
| 2017 | 30.51 Billion KRW | 38.14% |
| 2016 | 22.09 Billion KRW | 96.02% |
| 2015 | 11.27 Billion KRW | 8.08% |
| 2014 | 10.42 Billion KRW | -0.54% |
| 2013 | 10.48 Billion KRW | 1.16% |
| 2012 | 10.36 Billion KRW | 15.14% |
| 2011 | 9 Billion KRW | 18.06% |
| 2010 | 7.62 Billion KRW | -6.99% |
| 2009 | 8.19 Billion KRW | 25.87% |
| 2008 | 6.51 Billion KRW | 3.28% |
| 2007 | 6.3 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.08 Billion KRW | -16.76% |
| 2024 Q2 | 7.9 Billion KRW | 11.55% |
| 2023 FY | 33.38 Billion KRW | -32.44% |
| 2023 Q1 | 11.6 Billion KRW | -18.76% |
| 2023 Q2 | 8.18 Billion KRW | -29.47% |
| 2023 Q3 | -10.55 Billion KRW | -228.96% |
| 2023 Q4 | 8.51 Billion KRW | 180.66% |
| 2022 Q2 | 15.6 Billion KRW | 51.36% |
| 2022 Q3 | 9.22 Billion KRW | -40.84% |
| 2022 FY | 49.41 Billion KRW | 36.27% |
| 2022 Q4 | 14.28 Billion KRW | 54.74% |
| 2022 Q1 | 10.3 Billion KRW | -5.13% |
| 2021 Q1 | 5.34 Billion KRW | -48.53% |
| 2021 FY | 36.26 Billion KRW | 21.4% |
| 2021 Q4 | 10.86 Billion KRW | 18.21% |
| 2021 Q2 | 10.86 Billion KRW | 103.25% |
| 2021 Q3 | 9.19 Billion KRW | -15.4% |
| 2020 Q4 | 10.38 Billion KRW | 60.09% |
| 2020 FY | 29.87 Billion KRW | 41.58% |
| 2020 Q3 | 6.48 Billion KRW | -18.36% |
| 2020 Q2 | 7.94 Billion KRW | 57.26% |
| 2020 Q1 | 5.05 Billion KRW | -16.52% |
| 2019 FY | 21.09 Billion KRW | -3.91% |
| 2019 Q1 | 4.19 Billion KRW | -33.62% |
| 2019 Q2 | 6.73 Billion KRW | 60.62% |
| 2019 Q3 | 4.39 Billion KRW | -34.79% |
| 2019 Q4 | 6.05 Billion KRW | 37.84% |
| 2018 Q3 | 4.21 Billion KRW | -27.87% |
| 2018 Q4 | 6.31 Billion KRW | 49.75% |
| 2018 Q2 | 5.84 Billion KRW | 4.86% |
| 2018 Q1 | 5.57 Billion KRW | -44.78% |
| 2018 FY | 21.95 Billion KRW | -28.05% |
| 2017 Q1 | 6.03 Billion KRW | -14.79% |
| 2017 Q3 | 5.52 Billion KRW | -37.61% |
| 2017 Q4 | 10.09 Billion KRW | 82.76% |
| 2017 FY | 30.51 Billion KRW | 38.14% |
| 2017 Q2 | 8.85 Billion KRW | 46.64% |
| 2016 Q4 | 7.08 Billion KRW | 33.47% |
| 2016 FY | 22.09 Billion KRW | 96.02% |
| 2016 Q3 | 5.31 Billion KRW | -22.83% |
| 2016 Q2 | 6.88 Billion KRW | 144.65% |
| 2016 Q1 | 2.81 Billion KRW | -6.73% |
| 2015 Q1 | 2.4 Billion KRW | -15.96% |
| 2015 Q3 | 2.37 Billion KRW | -31.51% |
| 2015 FY | 11.27 Billion KRW | 8.08% |
| 2015 Q4 | 3.01 Billion KRW | 26.91% |
| 2015 Q2 | 3.46 Billion KRW | 44.04% |
| 2014 Q4 | 2.86 Billion KRW | 22.81% |
| 2014 FY | 10.42 Billion KRW | -0.54% |
| 2014 Q3 | 2.33 Billion KRW | -11.11% |
| 2014 Q2 | 2.62 Billion KRW | 0.9% |
| 2014 Q1 | 2.6 Billion KRW | -34.38% |
| 2013 Q2 | 2.46 Billion KRW | 19.13% |
| 2013 Q1 | 2.07 Billion KRW | -44.54% |
| 2013 Q3 | 1.97 Billion KRW | -20.02% |
| 2013 Q4 | 3.96 Billion KRW | 100.76% |
| 2013 FY | 10.48 Billion KRW | 1.16% |
| 2012 FY | 10.36 Billion KRW | 15.14% |
| 2012 Q2 | 2.45 Billion KRW | 73.65% |
| 2012 Q3 | 1.95 Billion KRW | -20.23% |
| 2012 Q4 | 3.73 Billion KRW | 91.03% |
| 2012 Q1 | 1.41 Billion KRW | 0.0% |
| 2011 Q3 | 592.62 Million KRW | -66.11% |
| 2011 FY | 9 Billion KRW | 18.06% |
| 2011 Q2 | 1.74 Billion KRW | 84.15% |
| 2011 Q1 | 949.64 Million KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 FY | 7.62 Billion KRW | -6.99% |
| 2010 Q3 | 1.04 Billion KRW | 0.42% |
| 2010 Q2 | 1.03 Billion KRW | -4.27% |
| 2010 Q1 | 1.08 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2009 Q2 | 824.03 Million KRW | -32.73% |
| 2009 Q3 | 1.13 Billion KRW | 37.5% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 8.19 Billion KRW | 25.87% |
| 2009 Q1 | 1.22 Billion KRW | -23.91% |
| 2008 Q3 | 1.47 Billion KRW | -16.28% |
| 2008 Q4 | 1.6 Billion KRW | 9.05% |
| 2008 FY | 6.51 Billion KRW | 3.28% |
| 2008 Q2 | 1.76 Billion KRW | 6.04% |
| 2008 Q1 | 1.66 Billion KRW | -4.31% |
| 2007 Q4 | 1.73 Billion KRW | 6.11% |
| 2007 Q2 | 1.75 Billion KRW | 47.99% |
| 2007 Q3 | 1.63 Billion KRW | -6.43% |
| 2007 Q1 | 1.18 Billion KRW | 0.0% |
| 2007 FY | 6.3 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ORIENT BIO Inc. | 10.23 Billion KRW | -296.944% |
| Green Cross Holdings Corporation | 620.02 Billion KRW | 93.45% |
| Green Cross Holdings Corporation | 424.43 Billion KRW | 90.432% |
| Pharmicell Co., Ltd. | 14 Billion KRW | -189.976% |
| Green Cross Corporation | 424.43 Billion KRW | 90.432% |
| Celltrion, Inc. | 359.46 Billion KRW | 88.703% |
| Samsung Biologics Co.,Ltd. | 638.51 Billion KRW | 93.64% |
| SK bioscience Co.,Ltd. | 154.23 Billion KRW | 73.67% |
| SK Biopharmaceuticals Co., Ltd. | 358.33 Billion KRW | 88.667% |
| Prestige BioPharma Limited | 63.47 Billion KRW | 36.021% |